ATS 2019 Virtual Final Program

10:15 PRO: Patients With Rapidly Progressive ILD Should Be Offered ECMO D. Brodie, MD, New York, NY 10:27 CON: Patients With Rapidly Progressive ILD Should Not Be Offered ECMO J. M. Walter, MD, Chicago, IL 10:39 Rebuttal D. Brodie, MD, New York, NY 10:45 PRO: An IPAF Designation Provides Useful Prognostic Information to the Evaluation of Idiopathic Interstitial Pneumonia M.E. Strek, MD, ATSF, Chicago, IL 10:57 CON: The IPAF Criteria Need to Be Refined Prior to Widespread Implementation A.U. Wells, MD, London, United Kingdom 11:09 Rebuttal M.E. Strek, MD, ATSF, Chicago, IL This session and the International Conference are supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests. BEHAVIORAL • CLINICAL CRITICAL CARE TRACK CME Credits Available: 2 A4 DO I HAVE TO? RE-EVALUATING COMMON PRACTICES IN THE ICU Assemblies on Critical Care; Behavioral Science and Health Services Research; Nursing 9:15 a.m. - 11:15 a.m. OMNI DALLAS DOWNTOWN Dallas Ballroom D/H (Level 3) Target Audience Critical care clinicians (fellows, attending physicians, NPs/PAs/CRNAs, nurses, allied health professionals), critical care researchers, ICU administrators Objectives At the conclusion of this session, the participant will be able to: • identify practices which may be commonplace, yet without clear reason; • understand the data (for, against, or absent) in relation to these commonplace practices; • understand why changing practice in the ICU setting is hard and how we may move towards better achieving desired change. Much of what we do in the ICU is done because, well, “that’s just the way we do things.” Over time, well-accepted standards of care have, when studied, been found to be of no benefit (e.g., pulmonary artery catheters) and/or potential harm (e.g., sedation to coma) to patients. There remain, however, many things we do every day which, upon closer inspection, have little basis for being the mainstay of practice. In this session, we will delve into the data (or lack thereof) underpinning several of these routine practices, and we will consider what may happen if (gasp), we stopped doing them. Chairing: H.B. Gershengorn, MD, ATSF, Miami, FL M. Hua, MD, MSci, New York, NY K. Hibbert, MD, Boston, MA 9:15 Why It’s Necessary to Challenge Practice That Has Become Dogma H.B. Gershengorn, MD, ATSF, Miami, FL 9:25 Do I Have to Use a Central Line to Deliver Vasopressors? J. Cardenas-Garcia, MD, Ann Arbor, MI 9:40 Do I Have to Limit the Number of Visitors in the ICU? S. Beesley, MD, Salt Lake City, UT 9:55 Do I Have to Use Stylets for Intubation in the ICU? M. Hua, MD, MSci, New York, NY 10:10 Do I Have to Withhold IV Contrast from CT Scans for Critically Ill Patients? K. Kashani, MD, MSc, Rochester, MN 10:25 Do I Have to Obtain Imaging Studies for Altered Mental Status in the ICU? H. Wunsch, MSc, MD, Toronto, Canada 10:40 Do I Have to Keep All My Patients on Supplemental Oxygen? M. Girardis, MD, Modena, Italy 10:55 Why It’s Difficult to Change Practice That Has Become Dogma G.D. Rubenfeld, MD, MSc, Toronto, Canada 11:05 Questions and Answers K. Hibbert, MD, Boston, MA BASIC • CLINICAL • TRANSLATIONAL BASIC SCIENCE CORE CME Credits Available: 2 A5 CELL FATE DETERMINATION IN THE LUNG IN HEALTH AND DISEASE: LOCATION AND NEIGHBORS MATTER Assemblies on Allergy, Immunology and Inflammation; Critical Care; Environmental, Occupational and Population Health; Pediatrics; Pulmonary Infections and Tuberculosis; Respiratory Cell and Molecular Biology; Respiratory Structure and Function; Thoracic Oncology 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom D Two (Level 3) Target Audience Providers of lung health; those serving patients with COPD, ILD, pulmonary vascular disease; those with clinical and research responsibilities; those needing instruction in areas of medicine outside of their specialty. Objectives At the conclusion of this session, the participant will be able to: • learn new findings about the different types of stem and progenitor cell types in the lung and how these participate in development and in repair after injury; • integrate this knowledge related to the evolving field of regenerative medicine and stem cell therapy; • review the scientific and medical literature and expert opinion of members of the Science Core of the ATS. ATS 2019 • Dallas, TX 26 SUNDAY • MAY 19